Literature DB >> 2752109

Molecular defects of factor IX Chicago-2 (Arg 145----His) and prothrombin Madrid (Arg 271----cys): arginine mutations that preclude zymogen activation.

D L Diuguid1, M J Rabiet, B C Furie, B Furie.   

Abstract

Factor IX Chicago-2 and prothrombin Madrid were purified from patients with hemophilia B and congenital dysprothrombinemia, respectively. Each protein displays defects in zymogen activation secondary to the failure to cleave one of the sessile bonds whose cleavage is necessary for full coagulant activity. These proteins were isolated by immunoaffinity chromatography using conformation-specific antibodies directed at either factor IX or prothrombin. Factor IX Chicago-2 is cleaved abnormally by factor XIa, yielding a pattern consistent with the failure to cleave the sessile bond between Arg 145 and Ala 146. Prothrombin Madrid is cleaved abnormally by factor Xa, yielding a pattern consistent with the failure to cleave the sessile bond between Arg 271 and Thr 272. Peptide mapping was performed on reduced and alkylated factor IX, factor IX Chicago-2, prothrombin, and prothrombin Madrid, and the hydrolysates were separated by high-performance liquid chromatography. The mutant peptide in factor IX Chicago-2 was identified by automated Edman degradation as residues 143 through 188 of factor IX, and had a histidine substituted for arginine at residue 145. The mutant peptide identified in prothrombin Madrid corresponds to residues 267 through 285 of prothrombin and has the substitution of cysteine for arginine at residue 271. These mutations, each occurring at arginines, are identical to those in factor IX Chapel Hill and prothrombin Barcelona. These results suggest that a limited repertoire of point mutations, many affecting arginine residues, may be responsible for hereditary defects of the vitamin K-dependent proteins in patients with normal antigen levels.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2752109

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  11 in total

1.  Haemophilia B: database of point mutations and short additions and deletions--second edition.

Authors:  F Giannelli; P M Green; K A High; S Sommer; D P Lillicrap; M Ludwig; K Olek; P H Reitsma; M Goossens; A Yoshioka
Journal:  Nucleic Acids Res       Date:  1991-04-25       Impact factor: 16.971

2.  Haemophilia B: database of point mutations and short additions and deletions--fourth edition, 1993.

Authors:  F Giannelli; P M Green; K A High; S Sommer; M C Poon; M Ludwig; R Schwaab; P H Reitsma; M Goossens; A Yoshioka
Journal:  Nucleic Acids Res       Date:  1993-07-01       Impact factor: 16.971

3.  Cysteamine enhances the procoagulant activity of Factor VIII-East Hartford, a dysfunctional protein due to a light chain thrombin cleavage site mutation (arginine-1689 to cysteine).

Authors:  A M Aly; M Arai; L W Hoyer
Journal:  J Clin Invest       Date:  1992-05       Impact factor: 14.808

4.  Haemophilia B: database of point mutations and short additions and deletions, fifth edition, 1994.

Authors:  F Giannelli; P M Green; S S Sommer; D P Lillicrap; M Ludwig; R Schwaab; P H Reitsma; M Goossens; A Yoshioka; G G Brownlee
Journal:  Nucleic Acids Res       Date:  1994-09       Impact factor: 16.971

5.  Why does the human factor IX gene have a G + C content of 40%?

Authors:  C D Bottema; M J Bottema; R P Ketterling; H S Yoon; R L Janco; J A Phillips; S S Sommer
Journal:  Am J Hum Genet       Date:  1991-10       Impact factor: 11.025

6.  Haemophilia B (sixth edition): a database of point mutations and short additions and deletions.

Authors:  F Giannelli; P M Green; S S Sommer; M C Poon; M Ludwig; R Schwaab; P H Reitsma; M Goossens; A Yoshioka; G G Brownlee
Journal:  Nucleic Acids Res       Date:  1996-01-01       Impact factor: 16.971

7.  Limiting prothrombin activation to meizothrombin is compatible with survival but significantly alters hemostasis in mice.

Authors:  Maureen A Shaw; Keith W Kombrinck; Kathryn E McElhinney; David R Sweet; Matthew J Flick; Joseph S Palumbo; Mei Cheng; Naomi L Esmon; Charles T Esmon; Alexander Brill; Denisa D Wagner; Jay L Degen; Eric S Mullins
Journal:  Blood       Date:  2016-06-01       Impact factor: 22.113

8.  Factor XKetchikan: a variant molecule in which Gly replaces a Gla residue at position 14 in the light chain.

Authors:  D J Kim; A R Thompson; H L James
Journal:  Hum Genet       Date:  1995-02       Impact factor: 4.132

9.  F9 missense mutations impairing factor IX activation are associated with pleiotropic plasma phenotypes.

Authors:  Alessio Branchini; Massimo Morfini; Barbara Lunghi; Donata Belvini; Paolo Radossi; Loredana Bury; Maria Luisa Serino; Paola Giordano; Dorina Cultrera; Angelo Claudio Molinari; Mariasanta Napolitano; Elisabetta Bigagli; Giancarlo Castaman; Mirko Pinotti; Francesco Bernardi
Journal:  J Thromb Haemost       Date:  2021-10-24       Impact factor: 16.036

10.  Cooperative regulation of the activity of factor Xa within prothrombinase by discrete amino acid regions from factor Va heavy chain.

Authors:  Melissa A Barhoover; Tivadar Orban; Michael A Bukys; Michael Kalafatis
Journal:  Biochemistry       Date:  2008-12-02       Impact factor: 3.162

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.